Lightnews — Scholar-powered news

Reposted by Nicolas Villain

L’Express @lexpress.fr · 2d

Médicaments anti-Alzheimer, le débat est nécessaire : l’appel d’un collectif de scientifiques
➡️ https://l.lexpress.fr/r90

1 1

Reposted by Nicolas Villain

Fondation Recherche Alzheimer @alzheimer-recherche.org · Jun 2

Merci au Dr @nvillain-alz.bsky.social pour sa présentation sur les nouveaux traitements par immunothérapie #alzheimer #traitements.

1 2

Reposted by Nicolas Villain

European Journal of Neurology @europeanjournalofneurology.ean.org · May 13

🎉 We’re now on BlueSky!
Follow the European Journal of Neurology 👉 @europeanjournalofneurology.ean.org
Stay up-to-date with the latest in #Neurology!
#MedSky #NeuroSky

2 4

Reposted by Nicolas Villain

Trey Bateman @renegadesynapse.bsky.social · May 7

Part 1 focused on patient selection challenges. Part 2 will focus on health system readiness. Tara Carlisle and myself were co-first authors on these and benefited greatly from our senior author, Kirk Daffner.

1 1

Reposted by Nicolas Villain

Trey Bateman @renegadesynapse.bsky.social · May 7

The American Neuropsychiatric Association (No bsky, yet..) dementia special interest group, which I've been the leader of for a number of years, has been working on a two part series for the Journal of Neuropsychiatry and Clinical Neuroscience. Part 1 here.

www.psychiatryonline.org/doi/10.1176/...

Antiamyloid Monoclonal Antibodies in Alzheimer’s Disease, Part 1: Patient Selection | The Journal of Neuropsychiatry and Clinical Neurosciences

The availability of monoclonal antibodies directed against amyloid beta, for use as disease-modifying therapies for Alzheimer’s disease (AD), represented a major shift in the field of AD research and ...

www.psychiatryonline.org

1 2 3

Reposted by Nicolas Villain

Danielle Beckman @daniellebeckman.bsky.social · May 5

"We call on researchers worldwide to unite and join us ... If you love freedom, come and help us stay free," French President Emmanuel Macron said at Paris' Sorbonne University
#BrainDrain
www.reuters.com/science/eus-...

EU's Von der Leyen announces 500 mln euro package to lure top researchers to Europe

European Commission President Ursula von der Leyen announced on Monday a 500 million euros ($566.6 million) incentive package to boost European science research, as Europe hopes to lure top U.S. scientists disgruntled with President Donald Trump.

www.reuters.com

14 38

Reposted by Nicolas Villain

Fondation Recherche Alzheimer @alzheimer-recherche.org · May 2

RV le 2 juin pour les #EntretiensAlzheimer : avancées de la recherche, nouveaux traitements, prédiction de la maladie… avec @nvillain-alz.bsky.social et #AudreyGabelle Gratuit sur inscription 👉 entretiensalzheimer.org/index.php/il...

1 2

Reposted by Nicolas Villain

Nature @nature.com · Apr 27

Scientists must push back against the threat of rising white nationalism and the dangerous and pseudoscientific ideas of eugenics

https://go.nature.com/42Zryw1

Eugenics is on the rise again: human geneticists must take a stand

Nature - Scientists must push back against the threat of rising white nationalism and the dangerous and pseudoscientific ideas of eugenics.

go.nature.com

3 99 210

Reposted by Nicolas Villain

Robin de Flores @robindeflores.bsky.social · Apr 24

🧠 PhD position available!

Study polypathology in the medial temporal lobe at the Paris Brain Institute with @lemwisse.bsky.social , @nvillain-alz.bsky.social and myself.

This exciting project combines neuroimaging, neuropathology and cognition!

Please share widely 🙏

Laura Wisse @lemwisse.bsky.social · Apr 23

Super excited to announce a PhD position on polypathology in the medial temporal lobe at the Paris Brain Institute together with @nvillain-alz.bsky.social and @robindeflores.bsky.social!

offres.institutducerveau-icm.org/fr/jobs/1935...

Please repost!

Nos super offres || PhD - polypathology in the medial temporal lobe

offres.institutducerveau-icm.org

8 6

Nicolas Villain @nvillain-alz.bsky.social · Apr 23

Exciting opportunity for a PhD position at the @institutducerveau.bsky.social on a European collaborative project under the supervision of medial temporal lobe specialists!
Spread the word!

bsky.app/profile/lemw...

Laura Wisse @lemwisse.bsky.social · Apr 23

Super excited to announce a PhD position on polypathology in the medial temporal lobe at the Paris Brain Institute together with @nvillain-alz.bsky.social and @robindeflores.bsky.social!

offres.institutducerveau-icm.org/fr/jobs/1935...

Please repost!

Nos super offres || PhD - polypathology in the medial temporal lobe

offres.institutducerveau-icm.org

1 1

Reposted by Nicolas Villain

Vincent Planche @vincentplanche.bsky.social · Apr 17

am pleased to share our letter, highlighting that the science does not yet support regulatory approval of amyloid-targeting therapies for AD based solely on biomarker evidence.
alz-journals.onlinelibrary.wiley.com/doi/full/10....

The science does not yet support regulatory approval of amyloid‐targeting therapies for Alzheimer's disease based solely on biomarker evidence

Click on the article title to read more.

alz-journals.onlinelibrary.wiley.com

3 5 12

Reposted by Nicolas Villain

ANSM @ansm-gouv.bsky.social · Apr 10

💊Les médicaments contre l’anxiété, c’est pour une courte durée. Ceux contre l’insomnie, c’est pour quelques nuits !

↪️Découvrez notre campagne pour favoriser le #BonUsage des médicaments contre l’anxiété et l’insomnie sévères👉http://lesmedicamentsetmoi.fr

#MedicamentsEtMoi #GCN2025

220 12 30

Nicolas Villain @nvillain-alz.bsky.social · Apr 15

Absolutely! I'm celebrating for the 85%! :)

Nicolas Villain @nvillain-alz.bsky.social · Apr 15

The favorable R/B ratio remains*

1

Nicolas Villain @nvillain-alz.bsky.social · Apr 15

It could also be argued that this subgroup hasn't proved efficacy. Therefore, the R/B ratio remains to be proven considering the significant safety signal

2

Nicolas Villain @nvillain-alz.bsky.social · Apr 15

2/
C) The key question: if excluded from treatment, what enhanced support/follow-up do we offer? What research for this vulnerable group?
The APOLLOE4 trial is an example of an active engagement into this direction!

1

Nicolas Villain @nvillain-alz.bsky.social · Apr 15

1/ Indeed, an important milestone with EMA approval of lecanemab! Is it genetic discrimination? I beg to disagree :)
A) Not all inequality is inequity — in oncology, genetics often guides access.
B) Feels like double jeopardy: highest risk, yet denied treatment. But safety data matters.

1 1

Reposted by Nicolas Villain

Dave Weisman @dweisman.bsky.social · Apr 15

Great news today. Lecanemab approved in Europe. I quibble with the fact that genetic discrimination is permitted, but this probably won’t last long.

Nicolas Villain @nvillain-alz.bsky.social · Apr 15

Oh! It was finally approved today! 🍾🍾

ec.europa.eu/newsroom/san...

HEALTH AND FOOD SAFETY - Commission authorises medicine for treatment of early Alzheimer’s disease

ec.europa.eu

2 3 6

Nicolas Villain @nvillain-alz.bsky.social · Apr 15

Oh! It was finally approved today! 🍾🍾

ec.europa.eu/newsroom/san...

HEALTH AND FOOD SAFETY - Commission authorises medicine for treatment of early Alzheimer’s disease

ec.europa.eu

2 6

Nicolas Villain @nvillain-alz.bsky.social · Apr 15

I mean, now the decision relies on the European Commission directly as the dedicated committees could not make a decision

1

Nicolas Villain @nvillain-alz.bsky.social · Apr 15

Here is the full list:
Ursula von der Leyen & Co

commission.europa.eu/about/organi...

College of Commissioners

Get to know the 27 European Commissioners of the von der Leyen Commission (2024-2029), who define the Commission’s political strategy and propose EU laws and policies.

commission.europa.eu

1

Nicolas Villain @nvillain-alz.bsky.social · Apr 15

« The European Commission (EC) is the primary executive arm of the European Union (EU). It operates as a cabinet government »

en.wikipedia.org/wiki/Europea...

European Commission - Wikipedia

en.wikipedia.org

1

Nicolas Villain @nvillain-alz.bsky.social · Apr 14

10/ The science is on the table. The @ema.europa.eu's CHMP has spoken. The clinics are ready. It’s time for the @ec.europa.eu to act.
#Alzheimers #EuropeanCommission #lecanemab #EMA #neurology

Nicolas Villain @nvillain-alz.bsky.social · Apr 14

9/ Full disclosure: I have no direct financial or strategic ties to the pharma industry. For transparency, see: www.transparence.sante.gouv.fr/pages/infosb...

Infos Bénéficiaires — Transparence Santé

La base de données publique Transparence - Santé rend accessible l'ensemble des informations déclarées par les entreprises sur les liens d'intérêts qu'elles entretiennent avec les acteurs du secteur d...

www.transparence.sante.gouv.fr

1

Nicolas Villain @nvillain-alz.bsky.social · Apr 14

8/ Lecanemab will not stop Alzheimer’s. But for a subset of patients, it is a step forward. Let’s not trip over our own feet.

1